If you build medical devices, you will build a quality management system whether you call it that or not.
A QMS is simply the organized set of policies, procedures, records, and controls that prove you consistently build a device that is safe and effective, and that you can catch issues, fix them, and prevent them from happening again. It’s how you turn “we did the right thing” into “we can show you exactly how and when we did the right thing.”
The problem is that a lot of teams treat the QMS like a filing cabinet. In reality, it’s the operating system of your product lifecycle.
This article covers what a QMS is, the common frameworks you’ll hear about (FDA and ISO), and how Veridocx helps you connect QMS work directly to regulatory strategy and submissions so you’re not constantly rebuilding context.
What is a QMS?
A quality management system (QMS) is the formal structure your company uses to manage quality across the full device lifecycle. It defines:
What you do (policies and procedures)
How you do it (processes and responsibilities)
How you prove you did it (records, traceability, audit evidence)
In medtech, your QMS touches everything: design controls, risk management, document control, change control, supplier quality, CAPA, training, complaints, audits, and eventually postmarket surveillance. Even early stage teams feel this quickly because the first time you draft a submission, you’re forced to explain decisions that were made months ago.
That’s why we talk about regulatory as “decision architecture.” A QMS is the system that holds those decisions together long enough to be defensible.
The common QMS frameworks you’ll run into
FDA quality requirements (21 CFR Part 820) and what’s changing with QMSR
In the U.S., FDA’s quality requirements historically lived in 21 CFR Part 820 (the Quality System Regulation). FDA has now updated Part 820 through the Quality Management System Regulation (QMSR), aligning more closely with ISO 13485. FDA materials describing QMSR emphasize that it becomes effective on February 2, 2026, and incorporates ISO 13485:2016 by reference.
Practically, the takeaway is not “new rules dropped overnight.” The takeaway is that quality expectations are being harmonized, and teams who already operate with ISO style structure and traceability tend to be in a better place.
ISO 13485:2016
ISO 13485 is the internationally recognized QMS standard for medical devices. If you operate globally, sell into markets that expect ISO certification, or want a QMS structure that scales cleanly, you will hear ISO 13485 constantly. FDA’s QMSR approach explicitly aligns with ISO 13485:2016.
21 CFR Part 11
If you use electronic records and electronic signatures in a regulated context, Part 11 is the framework people reference for controls around integrity, audit trails, and signatures. Even if you are not “doing Part 11 validation” formally on day one, you still want systems and workflows that don’t create a compliance debt spiral later.
What’s inside a QMS in real life
Most QMS implementations include a few core “buckets” of work, and your evidence lives in the records you generate from those workflows.
Document control
Who approved what, when, what changed, and what version is current.
Design controls
How you translated user needs into design inputs, verified outputs, validated the final device, and maintained traceability across the whole chain.
Risk management
How you identified hazards, estimated risk, implemented controls, and proved those controls are effective.
Change control
How you assessed impact, reviewed, approved, and documented changes.
CAPA
How you investigated issues, implemented corrective actions, verified effectiveness, and prevented recurrence.
Training
Who is trained on what, and when.
Supplier quality
How suppliers are qualified, monitored, and controlled.
A QMS is not “a set of PDFs.” It’s the living structure that keeps those workflows connected.
Why QMS work feels painful for startups
The pain is rarely the idea of quality. It’s the fragmentation.
A decision about intended use sits in one doc. Risk controls sit in another. Labeling gets drafted late. Testing plans are made without a unified link back to the risk rationale. Then, when you go to write the submission, you’re forced to reconstruct how everything connects.
That’s exactly why we’re obsessive about upstream clarity. If your claims are sloppy, everything downstream gets harder. If you want the cleanest starting point, read our guide on Intended Use vs. Indications for Use and then our framework for Regulatory pathway and predicate decisions.
How Veridocx integrates QMS thinking into the regulatory workflow
Veridocx is built around a simple idea: quality and regulatory are not separate universes. They’re two views of the same decisions.
Here’s what that means in practice.
1. We connect claims, risk, and evidence early, not at submission time
Your intended use and indications aren’t just marketing language. They are the anchor for classification, risk framing, and what FDA expects you to prove. When those elements change late, teams get crushed by rework.
Veridocx is designed to keep the “why” attached to the “what” so when you update something upstream, you can see what it affects downstream. Pair this with our Medical device labeling and IFU guide because for many devices, labeling is not a formality, it’s a control mechanism.
2. We reduce the classic “QMS vs submission” disconnect
A lot of teams build quality artifacts without a clear view of how they map into an FDA narrative. Then the submission becomes a copy paste marathon, plus a panic audit trail hunt.
Veridocx is meant to make the submission feel like an organized export of work you already did, not a separate project that forces you to reinvent structure. If you’re submitting through eSTAR, our FDA eSTAR process guide is the operational companion to this, because formatting and completeness still matter and can absolutely slow teams down.
3. We make early alignment with FDA part of the system, not an afterthought
Strong teams de risk by engaging FDA before they sink months into testing and documentation in the wrong direction. That’s true whether you’re building a 510(k) strategy or heading toward De Novo.
Veridocx supports that strategy mindset by keeping your rationale and questions structured, which makes it easier to run an efficient Pre Sub and actually get useful feedback. If you want the playbook, start with FDA Pre Sub and Q Sub meetings.
4. We treat “quality readiness” as part of your business readiness
Fundraising, reimbursement strategy, and go to market planning all end up anchored to regulatory milestones. That’s why we like to keep regulatory and quality work legible to non regulatory stakeholders.
If you’re building your broader strategy stack, these pair well with QMS planning: FDA pathway selection for low risk devices, Regulatory pathway and predicate decisions, and even reimbursement framing like AMA CPT coding and reimbursement strategy.
The simple way to think about it
A QMS is how you make quality repeatable. A regulatory submission is how you make that work legible to FDA.
The teams who move fastest aren’t the ones who “write faster.” They’re the ones who keep the system connected so they don’t spend half their time reconstructing decisions.
That is what Veridocx is built for: connecting claims, controls, evidence, and submission structure into one traceable thread, so your QMS supports speed instead of feeling like overhead.
